DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Daiichi Sankyo
Daiichi Sankyo
National Cancer Institute (NCI)
Cancer Trials Ireland
Novartis
Novartis
Novartis
University of Ulm
Hoffmann-La Roche
Novartis
Novartis
Novartis
Novartis
National Cancer Institute (NCI)
Novartis
Institute of Cancer Research, United Kingdom
Hoffmann-La Roche
Consorzio Oncotech
GlaxoSmithKline
GBG Forschungs GmbH
GlaxoSmithKline
GlaxoSmithKline
National Cancer Institute (NCI)
GlaxoSmithKline